Practice Points Developed for Treatment of Outpatient COVID-19
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Sept. 20, 2023 -- In an updated clinical guideline issued by the American College of Physicians and published online Sept. 19 in the Annals of Internal Medicine, living, rapid practice points are presented for the outpatient treatment of confirmed COVID-19.
Amir Qaseem, M.D., Ph.D., from the American College of Physicians in Philadelphia, and colleagues developed living, rapid practice points focusing on 22 outpatient treatments for COVID-19, specifically relating to the omicron variant.
The authors note that molnupiravir should be considered for treating symptomatic patients with confirmed mild-to-moderate COVID-19 in the outpatient setting who are within five days of symptom onset and who have a high risk for progression to severe disease. For symptomatic patients with mild-to-moderate COVID-19 in the outpatient setting who are within five days of symptom onset and have a high risk for progression to severe disease, nirmatrelvir-ritonavir combination therapy should also be considered. Ivermectin should not be used for patients with confirmed mild-to-moderate COVID-19 in the outpatient setting. Sotrovimab should also not be used for patients with confirmed mild-to-moderate COVID-19 in the outpatient setting.
"More research evaluating the efficacy, effectiveness, and comparative effectiveness, as well as harms, of pharmacologic and biologic treatments of COVID-19 in the outpatient setting is needed, particularly in the context of changing dominant severe acute respiratory syndrome coronavirus 2 variants and subvariants," the authors write.
One author disclosed financial ties to Eli Lilly.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Further Support and Information on COVID-19
Read this next
Survival Possible for Some With TBI for Whom Treatment Was Withdrawn
MONDAY, May 13, 2024 -- A substantial proportion of patients with traumatic brain injury (TBI) who undergo withdrawal of life-sustaining treatment (WLST) could have survived and...
Study Identifies Factors Associated With Hydroxychloroquine Retinopathy
MONDAY, May 13, 2024 -- Factors associated with an increased risk for hydroxychloroquine retinopathy have been identified and include female sex, older age, and chronic kidney...
Adding Cardiovascular Biomarkers to Established Risk Factors Increases Risk Prediction
MONDAY, May 13, 2024 -- The addition of cardiovascular biomarkers to established risk factors leads to a small improvement in risk prediction of cardiovascular disease, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.